Paul Clement

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy

Dan P. Zandberg, Alain P. Algazi, Antonio Jimeno et al. · European Journal of Cancer · 2018 · 267 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 210 citations · Full text

Medicine, Oncology, Pharmacology +16

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Martin J. van den Bent, Marica Eoli, Juan Manuel Sepúlveda-Sánchez et al. · Neuro-Oncology · 2019 · 189 citations · Full text

Medicine, Oncology, Pharmacology +17

Atropine, Hyoscine Butylbromide, or Scopolamine Are Equally Effective for the Treatment of Death Rattle in Terminal Care

Hans Wildiers, Chris Dhaenekint, Peter Demeulenaere et al. · Journal of Pain and Symptom Management · 2009 · 107 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab

Tine Loyson, Thomas Van Cann, Patrick Schöffski et al. · Acta Clinica Belgica · 2017 · 59 citations

Medicine, Oral Medicine, Bone Metabolism +13